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Abstract
Background: The prevalence of hypogonadism in HIV-infected patients is still a matter of debate as there is no
standardized consensual diagnostic method. In addition, the etiology and endocrine/metabolic implications of
hypogonadism in this population remain controversial. This study aims to determine the prevalence of testosterone
deficiency in a single-site hospital and to evaluate its association with potential risk factors, lipodystrophy, metabolic
syndrome, and cardiovascular risk.
Methods: This study analyzed 245 HIV-infected men on combined antiretroviral therapy. Patients with low total
testosterone (TT) levels (<2.8 ng/mL) and/or low calculated free testosterone (FT) levels (<6.5 ng/dL) were
considered testosterone deficient. According to their LH and FSH levels, patients were classified as having
hypogonadotropic or hypergonadotropic dysfunction. Other clinical, anthropometric, and analytic parameters
were also collected and analyzed.
Results: The prevalence of testosterone deficiency in our population was 29.4 %. Among them, 56.9 % had
hypogonadotropic dysfunction and 43.1 % presented with hypergonadotropic dysfunction. Patients with
testosterone deficiency were older (p < 0.001), had higher HbA1c levels (p = 0.016) and higher systolic blood
pressure (p = 0.007). Patients with lower testosterone levels had higher prevalence of isolated central fat
accumulation (p = 0.015) and had higher median cardiovascular risk at 10 years as measured by the Framingham Risk
Score (p = 0.004) and 10-Year ASCVD risk (p = 0.002).
Conclusions: The prevalence of testosterone deficiency in this HIV population is high, with hypogonadotropic
dysfunction being responsible for the majority of cases. Testosterone deficiency might predispose to, or be involved, in
the pathogenesis of HIV-associated lipodystrophy. Patients with low testosterone levels have higher cardiovascular risk,
highlighting the importance of early diagnosis of this condition.
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Background
Several endocrine abnormalities, like hypogonadism,
thyroid dysfunction, adrenal insufficiency, and diabetes
were described as more prevalent in HIV patients in the
pre-combined antiretroviral therapy (cART) era. They
were mainly associated to HIV-related opportunistic in-
fections and advanced multi-organ failure [1–3]. With
the advent of highly active antiretroviral therapy in the
1990s, some of these metabolic diseases have waned but
hypogonadism and diabetes remain frequent endocrino-
pathies in these patients [4].
Gonadal dysfunction leads to sexual impairment, bone
and muscle mass loss, changes in body fat mass, fatigue,
cognitive impairment, depressed mood and anemia, af-
fecting the overall quality of life [1, 5, 6]. After assessing
testosterone levels, additional tests are needed to determine
whether hypogonadism is primary (hypergonadotropic), or
secondary (hypogonadotropic) [1, 7]. According to previous
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studies in this population, hypogonadotropic dysfunction is
responsible for the majority of cases, while primary disease
is seen less frequently (occasionally, patients may have a
combination of both). [8]. Overall, the causes of testoster-
one deficiency among HIV-infected men remain controver-
sial, and there is lack of studies concerning the etiology and
metabolic and endocrine consequences of this condition
[1]. Additionally, the prevalence of testosterone deficiency
in the HIV population is not well defined, ranging from 16
to 54 %, as slightly different criteria are adopted in different
studies [4, 6, 9].
Therefore, this study aims to determine the prevalence
of testosterone deficiency in a population of HIV-
infected men under cART, as well as the prevalence of
hypo- and hypergonadotropic dysfunction. Additionally,
it aims to assess the association between testosterone
deficiency and potential risk factors, and to evaluate the
relationship between lower testosterone levels, lipody-
strophy, metabolic syndrome and cardiovascular risk.
Methods
Subjects
Two-hundred and forty five adult men with serologically
documented HIV infection on cART were evaluated at
the Endocrinology Outpatient Department of Centro
Hospitalar São João (a tertiary center in Northern
Portugal). Patients were consecutively referred from
the Infectious Diseases Clinic between January/2008
to December/2014, and were enrolled in the first visit.
Patients with acute or severe illness, previous treat-
ment with androgen-derived agents and concurrent
endocrinopathy (e.g. uncontrolled hypothyroidism, ad-
renal insufficiency, hyperprolactinemia, known pituitary
disease) were excluded.
Clinical assessment
For all patients, the following information was collected,
using a standardized protocol: age, time since HIV
diagnosis, risk factor for HIV transmission, type and
duration of cART exposure, CD4+ count, plasmatic HIV
RNA load, smoking history (current, past, or never) and
alcohol consumption (yes or no). HIV stages were defined
using the Centers for Disease Control and Prevention’s
(CDC) classification into asymptomatic (A), symptomatic
(B) and AIDS (C) [10].
Height was measured in the standing position, using a
wall stadiometer (Holtain Limited Crymych, Dyfed®), and
body weight was measured using the TANITA (Tanita®,
model TBF 300) scale. Circumferences of neck, waist, hip,
thigh and arm were measured, as previously described,
and blood pressure (BP) was measured using the current
recommendations [11, 12].
Clinical lipodystrophy was assessed by both patient
and practitioner, and was defined as peripheral lipoatrophy,
with or without central fat accumulation [12]. Abdominal
prominence (central obesity) was defined by a waist cir-
cumference >102 cm, as defined by NCEP-ATP III modi-
fied criteria for metabolic syndrome [13]. All clinical
assessments were performed by the same observer. Patients
were classified into four different groups: (1) No lipodystro-
phy (patients without clinical lipoatrophy and without ab-
dominal prominence); (2) Isolated central fat accumulation
(patients without clinical lipoatrophy and with abdominal
prominence); (3) Isolated lipoatrophy (patients with clinical
lipoatrophy and without abdominal prominence), and; (4)
Mixed forms of lipodystrophy (patients with clinical lipoa-
trophy and with abdominal prominence) [11].
Laboratory analysis
An early morning venous blood sample was taken after
a 12-hour overnight fast. All samples were analyzed at
the central laboratory of our hospital. Total testosterone
(TT), sex hormone binding globulin (SHBG), luteinizing
hormone (LH), and follicle-stimulating hormone (FSH)
were determined using Cobas e411 (Roche Diagnostic).
Glycosylated hemoglobin (HbA1c) was measured by
Variant II Turbo (Bio-Rad). To evaluate lipid profile, we
measured total cholesterol, LDL cholesterol (LDL-C),
HDL cholesterol (HDL-C) and triglycerides levels, using
Olympus AU5400 (BecKman Coulter). The CD4+ cell
count (×106 cell/L) and plasma HIV RNA loads were
assessed by flow cytometry and by a quantitative reverse
transcriptase polymerase chain reaction (Roche Diagnos-
tic), respectively.
Criteria for the definition of gonadal status
Testosterone deficiency was defined based on a serum
total testosterone (TT) below 2.8 ng/mL and/or a calcu-
lated free testosterone levels (FT), according to Vermeulen
formula, below 6.5 pg/mL [14].
According to the normal ranges for serum LH and
FSH, as defined by our central laboratory (1.7–8.3 mUI/
mL and 1.5–12.4 mUI/mL, respectively), patients were
assigned as having hypogonadotropic (low or normal LH
and/ or FSH) or hypergonadotropic dysfunction (high
LH and/ or FSH). Patients were classified as having high
sex hormone-binding globulin (SHBG) according to the
threshold value of 48.4 nmol/L.
Metabolic syndrome definition and cardiovascular risk
scores
We defined Metabolic Syndrome (MS) according to the
modified NCEP-ATP III criteria, requiring the presence
of three of the following risk factors: (1) elevated waist
circumference (>102 cm); (2) elevated triglycerides
(≥150 ml/dL or specific treatment); (3) reduced HDL-C
levels (<40 mg/dL), (4) elevated blood pressure (>130/
85 mmHg or treatment with anti-hypertensive drugs),
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and; (5) elevated fasting glucose (≥100 mg/dL or use of
glucose-lowering drugs) [13].
The cardiovascular disease (CVD) risk at 10 years was
measured by the Framingham Risk Score (FRS), using a
sex-specific algorithm that incorporates age, treated, and
untreated systolic blood pressure, HDL-C, total choles-
terol, glucose, and smoking status [15]. Based on the
Adult Treatment Panel III (ATP III) guidelines, individ-
uals were stratified into four risk categories: (1) Low risk
(0–1 CVD risk factors); (2) moderate risk (≥2 CVD risk
factors and a 10-year CVD risk <10 %); (3) moderately
high risk (≥2 CVD risk factors and a 10-year CVD risk
10–20 %), and; (4) high risk (CHD or CHD equivalent or
≥2 CVD risk factors and a 10-year CVD risk >20 %) [16].
The 10-year and lifetime atherosclerotic cardiovascular
disease (ASCVD) risk scores were calculated based on
the American College of Cardiology (ACC)/ American
Heart Association’s (AHA) guidelines. For all patients,
we used a sex, ethnic group and age-specific multivari-
able risk factor algorithm that incorporates total choles-
terol, HDL-C, untreated systolic blood pressure, diabetes
history, and smoking status [17].
Statistical analysis
Categorical variables were presented as absolute fre-
quencies and percentages, and were analyzed using Chi-
square or Fisher’s exact test. Continuous variables were
presented as medians and interquartile ranges, and were
analyzed using the Mann–Whitney U test. P values <0.05
were considered to be statistically significant. All statistical
analysis was performed using SPSS version 22.0 (SPSS,
Inc., Chicago, IL).
Results
A total of 245 HIV-infected males on cART were evaluated,
and 29.4 % were found to have testosterone deficiency, with
a median of TT and calculated FT of 2.6 ng/mL and
5.2 ng/dL, respectively. Among the patients with reduced
TT, 50 % had high SHBG levels.
In the group of patients with testosterone deficiency,
56.9 % had hypogonadotropic and 43.1 % had hypergona-
dotropic dysfunction. When different clinical, anthropo-
metric and analytic variables were analyzed regarding
these two categories of testosterone deficiency, patients
with elevated gonadotrophins presented a higher fre-
quency of NRTI use (100 % vs. 86.7 %; p = 0.028) and
lower CD4+ counts (336.0 vs. 449.0; p = 0.030). No other
differences were found between the two groups of
patients.
The baseline characteristics of our study population
are shown in Table 1. Patients with testosterone deficiency
were older than the remainder (median age of 51.5 versus








Age [years, median (IQR)] 48.0 (15.0) 51.5 (11.8) 48.0 (7.3) <0.001a
Duration of HIV infection [years, median (IQR)] 8.0 (6.0) 6.0 (8.0) 8.0 (6.0) 0.567a
HIV stage [n (%)]d
A 122 (52.1) 31 (44.9) 91 (55.2) 0.157b
B 12 (5.1) 6 (8.7) 6 (3.6)
C 100 (42.7) 32 (46.4) 68 (41.2)
cART [years, median (IQR)] 6.0 (7.0) 4.5 (8.8) 7.0 (6.0) 0.447a
NRTI [n (%)] 213 (86.9) 67 (31.5) 146 (84.4) 0.067c
NNRTI [n (%)] 104 (42.4) 33 (45.8) 71 (41.0) 0.489b
PI [n (%)] 119 (48.6) 33 (45.8) 86 (49.7) 0.580b
FI [n (%)] 1 (0.4) 0 1 (0.6) 0.999c
II [n (%)] 16 (6.5) 6 (8.3) 10 (5.8) 0.570c
Viral load (<50) [n (%)] 131 (82.4) 33 (76.7) 98 (84.5) 0.255b
CD4 count [cells/mm3, median (IQR)] 477.0 (327.3) 501.0 (351.5) 526.5 (286.8) 0.157a
HIV risk factor [n (%)]
Injecting drug user 55 (23.7) 18 (26.5) 37 (22.6) 0.561b
Heterosexual contact 118 (50.9) 37 (54.4) 81 (49.4)
Homosexual contact 50 (21.6) 11 (16.2) 39 (23.8)
Others 9 (3.9) 2 (2.9) 7 (4.3)
cART combined antiretroviral therapy, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, FI
fusion inhibitor, II integrase inhibitor
aMann-Whitney U test; bChi-square test, cFisher test; dInformation only available for 234 patients
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48.0 years; p < 0.001). No significant differences were ob-
served regarding the risk factors for HIV transmission,
stages of CDC criteria, length of HIV infection, and cART,
CD4+, viral count, viral suppression, and class of anti-
retroviral drugs used.
Table 2 shows the clinical characteristics of the popula-
tion studied. Patients with testosterone deficiency had a
significantly higher median waist circumference (99.5 cm
versus 93.0 cm; p = 0.030). Lower testosterone individuals
also presented a higher median HbA1c percentage (5.5 %
versus 5.3 %; p = 0.016) and a higher median systolic blood
pressure (133.5 mmHg versus 130.0 mmHg; p = 0.007).
There were no significant differences between the two
groups concerning weight, lipid profile, neck, upper-arm,
abdominal, and hip circumferences, smoking status, alco-
hol consumption and frequency of metabolic syndrome.
When patients were stratified into four groups of fat dis-
tribution (presence or not of clinical lipoatrophy and ab-
dominal prominence), patients with lower testosterone
levels had a higher percentage of isolated central fat accu-
mulation (18.1 % vs. 7.5 %; p = 0.015).
Patients with testosterone deficiency had a significantly
higher risk of CVD at 10 years, as measured by the FRS
(median score of 13.0 and 12.0; p = 0.004). Those patients
also presented a significantly higher 10-Year risk of CVD
with the ASCVD risk score (7.1 versus 6.8; p = 0.002), al-
though no significant differences were found concerning
lifetime ASCVD risk (p = 0.789).
Discussion
The introduction of cART has led to a decreased preva-
lence of hypogonadism among HIV-infected men. This
change is probably related to the reduced frequency of
end-stage AIDS, opportunistic infections, chronic immune
activation and HIV-associated wasting syndrome. How-
ever, hypogonadism remains an important problem in
HIV-infected patients, where higher rates of this condition
are found compared to the general population, even in pa-
tients with early stages of the disease [1, 18]. As previously
mentioned, the prevalence of hypogonadism in this popu-
lation is still a matter of debate, ranging from 16 to 54 %
in different reports [4, 6, 9]. This discrepancy might be
due to a lack of standardized, validated methods for its as-
sessment, and to a lack of universal agreement in a clinical
and/or biochemical definition for hypogonadism [19]. In
our study, we obtained a prevalence of testosterone defi-
ciency of 29.4 % in a population of 245 HIV-infected men
on cART. It has been recognized that testosterone levels
may be difficult to interpret in HIV-infected patients, as
they tend to have a higher concentration of SHBG, which
may increase TT values [1, 18, 20]. Therefore, following
the recommendations to use FT levels in individuals with
HIV infection, we used TT and FT calculated by the Ver-
meulen formula to define testosterone deficiency, in order
to avoid false negatives that would possible occur if only
TT levels had been used. Accordingly, if only serum TT
had been used, some patients with low testosterone levels
would have been missed as 50 % of them had high SHBG
levels [14, 21].
Regarding the categories of testosterone deficiency,
our results shows that hypogonadotropic dysfunction
was responsible for the majority of cases. This is in ac-
cordance with several studies that report a progressive
change in the etiology of testosterone deficiency in HIV-
infected patients. Publications in the pre-cART era re-
ported higher prevalences of gonadal dysfunction caused
by direct involvement by the virus with a reduction in
the Leydig cell number [22]. Recent investigations, after
the appearance of more effective therapy, showed a rela-
tively higher preponderance of secondary dysfunction
[6]. Several different mechanisms have been suggested to
explain the effect on the hypothalamic-pituitary-gonadal
(HPG) axis, including poor health status, undernutrition,
frailty, anti-retroviral drugs, the virus per se, opportunis-
tic infections and increased visceral adiposity [8].
Consistently with other studies, the presented data
shows that the prevalence of testosterone deficiency in-
creases with age, as it happens in the general population
However, there was no significant impact of the HIV
transmission risk factor and sexual orientation on testos-
terone levels, confirming the findings of other groups
[1]. With regards to the antiretroviral agents, our study
did not find any difference between patients with low
testosterone levels and the remaining ones among the
five studied pharmacologic groups. In fact, previous
studies show conflicting results in this area [1, 7, 18].
We have shown that 18.1 % of patients with testoster-
one deficiency presented visceral obesity (as measured
by waist circumference >102 cm), contrasting to 7.5 % of
eugonadal individuals. The lipodystrophy syndrome,
which has a reported prevalence of 41 % in HIV-infected
patients, is a well-known adverse effect of cART. It com-
prises fat redistribution abnormalities, insulin resistance
and dyslipidemia [7, 23]. However, the impact of cART
on the HPG axis is still not completely understood, and
little is known about the influence of sex hormone levels
on the development of lipodystrophy [23]. Testosterone
is one of the major determinants of regional distribution
of fat and body composition, favoring the accumulation
of visceral fat. The underlying pathophysiological mech-
anisms include an increase in tissue sensitivity to gluco-
corticoids, reduction of adipokines, and a reduction of
peroxisome proliferator-activated receptor (PPAR-γ) ac-
tivity [24]. Testosterone role in insulin sensitivity in
HIV-lipodystrophy has also been proposed since several
studies have shown that low levels of serum testosterone
correlate not only with central fat accumulation but also
with higher insulin levels [7].
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Weight [kg, median (IQR)] 76.3 (25.9) 71.3 (16.2) 0.857a
Height [cm, median (IQR)] 171.0 (8.0) 169.0 (7.5) 0.204a
BMI [(kg/m2), median (IQR)] 26.5 (16.8) 25.2 (5.4) 0.160a
Underweight [n (%)] 5 (7.0) 6 (3.6) 0.028b/0.155c
Normal weight [n (%)] 26 (36.3) 78 (46.2)
Overweight [n (%)] 23 (32.4) 67 (39.6)
Obesity [n (%)] 17 (23.9) 18 (10.7)
Neck circumference [cm, median (IQR)] 40.0 (4.8) 39.0 (3.0) 0.196a
Upper-arm circumference [cm, median (IQR)] 28.3 (3.8) 28.0 (3.8) 0.197a
Abdominal circumference [cm, median (IQR)] 98.0 (13.8) 93.0 (8.6) 0.492a
Waist circumference [cm, median (IQR)] 99.5 (19.8) 93.0 (13.5) 0.030a
Hip circumference [cm, median (IQR)] 47.0 (6.0) 47.5 (6.0) 0.906a
Metabolic syndrome [n (%)] 33 (45.8) 69 (39.9) 0.390b
Blood pressure [n (%)] 30 (41.7) 69 (40.1 %) 0.822b
Systolic blood pressure [median (IQR)] 133.5 (40.0) 130.0 (30.0) 0.007a
Diastolic blood pressure [median (IQR)] 79.0 (25.0) 80.0 (15.0) 0.756a
Smoking history [n (%)]
Current 21 (30.4) 72 (42.6) 0.127b
Former 25 (36.2) 42 (24.9)
Never 23 (33.3) 55 (32.5)
Alcohol consumption [n (%)] 41 (59.4) 77 (45.6) 0.052b
Total cholesterol [mg/dL, median (IQR)] 210.0 (69.0) 221.0 (70.5) 0.668a
LDL cholesterol [mg/dL, median (IQR)] 129.0 (37.0) 129.0 (72.8) 0.573a
HDL cholesterol [mg/dL, median (IQR)] 43.5 (13.3) 42.5 (13.3) 0.125a
Triglycerides [mg/dL, median (IQR)] 215.0 (215.3) 218.0 (162.0) 0.631a
HbA1c [%, median (IQR)] 5.5 (1.7) 5.3 (1.0) 0.016a
Total testosterone [ng/mL, median (IQR)] 2.6 (2.6) 5.9 (2.7) <0.001a
Free testosterone [ng/dL, median (IQR)] 5.2 (1.5) 9.1 (3.6) <0.001a
SHBG [nmol/L, median (IQR)] 35.2 (44.6) 46.6 (29.6) 0.083a
LH [mIU/mL, median (IQR)] 5.0 (4.9) 5.2 (3.2) 0.001a
FSH [mIU/mL, median (IQR)] 6.7 (7.1) 5.1 (4.1) <0.001a
FRS [median (IQR)] 13.0 (5.0) 12.0 (6.0) 0.004a
<10 [n (%)] 16 (22.2) 66 (38.2) 0.008b/0.003c
10–20 [n (%)] 48 (66.7) 101 (58.4)
>20 [n (%)] 8 (11.1) 6 (3.5)
10-Year ASCVD risk [%, median (IQR)] 7.1 (6.5) 6.8 (8.3) 0.002a
Lifetime ASCVD risk [n (%)]
<40 % 4 (10.0) 11 (8.0) 0.789b
40–50 % 22 (55.0) 84 (60.9)
>50 % 14 (35.0) 43 (31.2)
Lipodistrophy [n (%)] 39 (56.5) 96 (58.5) 0.776b
Waist circumference (>102 cm) [n(%)] 23 (31.9) 30 (17.3) 0.011b
No lipodystrophy [n (%)] 20 (27.8) 59 (34.3) 0.321b
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HIV-infected patients also present an increased cardio-
vascular risk when compared with the general population.
The pathogenesis of CVD in these patients is complex,
and several factors appear to be involved, including andro-
gen dysfunction [7, 25]. Low testosterone levels are inde-
pendently associated with cardiovascular risk and are
independent predictors of mortality [19, 26]. Accordingly,
in our study, HIV patients with lower testosterone levels
had a significantly higher 10-year risk of coronary heart
disease, as measured by the FRS and 10-Year ASCVD. We
could hypothesize that men with testosterone deficiency,
besides being older, are at additional CV risk due to the
higher frequency of hyperglycemia, abdominal obesity and
hypertension as described in our results. Regan et al. com-
pared the proportion of HIV patients with high predicted
10-year CVD risk using the FRS versus the ASCVD risk
prediction algorithm [27]. The authors reported that the
ASCVD algorithm classified a larger proportion of HIV
patients as high-risk, compared to the FRS. This is consist-
ent with our results, since a higher percentage of individ-
uals were classified as having a high-risk by the ASCVD
algorithm, independently of their testosterone status.
Nevertheless, no significant differences were found in the
lifetime risk of cardiovascular disease. This discrepancy
can possibly be explained by the fact that only patients
aged between 20 and 59 years-old could be included in
this score. Regardless, we should mention that both the
FRS and ASCVD appear to underestimate the actual risk
of events, as reported by Thompson-Paul et al. [28].
Therefore, risk assessment remains reliant on the use of
traditional risk factors, despite their inherent limitations.
To better estimate CVD risk, different models including
additional HIV-specific risk factors, such as immunologic
or virologic status, may need to be considered [25, 28].
Incorporation of imaging studies assessing subclinical
atherosclerosis in risk algorithms for HIV patients may
add useful information in the future [25].
This study has some limitations that are inherent to
the observational design and the cross-sectional nature
of our analyses. In addition, patients with testosterone
deficiency diagnosed prior to HIV infection were not ex-
cluded. Consequently, conclusions regarding causality
cannot be made with certainty. Although we have in-
cluded all patients referred to our department, bias in
the referral cannot be excluded, since some patients could
have been referred because they already had testosterone
deficiency or metabolic disorders related to cART.
Therefore, we might have selected a study population
where metabolic and endocrine complications were
over-represented.
Our study has some strong points, including the fact
that the study was performed in a highly experienced
unit in the assessment of metabolic and body fat abnor-
malities in HIV-infected patients, with all clinical assess-
ments being performed by the same investigator. Finally,
another positive point was the fact that our sample size
was relatively large when compared to other studies
performed in this area.
Conclusions
The prevalence of testosterone deficiency in HIV-infected
men is high, with hypogonadotropic dysfunction being re-
sponsible for the majority of cases. Patients with lower tes-
tosterone levels were older, had poorer glycemic control,
higher systolic blood pressure and increased waist circum-
ference. Our results corroborate the hypothesis that tes-
tosterone deficiency may predispose or might be involved
in the pathogenesis of HIV-associated lipodystrophy. This
has a significant clinical impact, since both conditions are
common in this population and are associated with a
negative impact on the quality of life and with poor ad-
hesion to therapy. Additionally, this study suggests that
patients with lower testosterone levels have higher car-
diovascular risk scores, highlighting the importance of
early diagnosis of this condition.
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